CD274 and non-small cell lung carcinoma: One such investigational approach involves BNT116, a personalized mRNA-based cancer vaccine, being evaluated in combination with the PD-1 inhibitor cemiplimab, in patients with advanced NSCLC exhibiting high PD-L1 expression.